Akebia Therapeutics (AKBA) Other Operating Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 11 years of Other Operating Expenses data on file, last reported at $707000.0 in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 0.86% year-over-year to $707000.0 in Q1 2026; TTM through Mar 2026 was $29.0 million, a 804.98% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 5.47% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $707000.0, down from $26.6 million in the prior quarter.
• Over the last five years, Other Operating Expenses for AKBA reached as high as $26.6 million in Q4 2025 and fell as low as $449000.0 in Q1 2022.
• Historically, Other Operating Expenses has averaged $2.3 million across 5 years, with a median of $852000.0 in 2022.
• Across the five-year window, Other Operating Expenses slumped 35.4% in 2022 and surged 2614.83% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $852000.0 in 2022, then grew by 0.47% to $856000.0 in 2023, then advanced by 14.25% to $978000.0 in 2024, then jumped by 2614.83% to $26.6 million in 2025, then slumped by 97.34% to $707000.0 in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $707000.0 in Q1 2026, $26.6 million in Q4 2025, and $896000.0 in Q3 2025.